1 During 1,190,170 person-years of follow-up (1982-2012),
there was no association between risk of hearing loss and hai
2 There was no association between stent fracture and the prima
3 There was no clear association between low- or high-fat dairy
4 Average urine oxalate excretion was 61 mg/day;
there was no correlation between fecal fat and urine oxalate
5 There was no correlation between subjective complaints and se
6 There was no difference between groups regarding demographics
7 There was no difference between groups regarding need for add
8 Although
there was no difference between groups with respect to common
9 r medical emergency team implementation across study sites,
there was no difference between predicted (hospital mean of 6
10 For the 20 patients who received intensive therapy,
there was no difference between the proportion of responding
11 s of follow-up (HR, 0.79 [95% CI, 0.69-0.91]; P=0.001), and
there was no difference in in-hospital morbidity.
12 In addition,
there was no difference in mean visual outcome of the first v
13 However,
there was no difference in nonfatal stroke, cardiovascular di
14 tive function was more frequent with WBRT than with SRS and
there was no difference in overall survival between the treat
15 ut task representations in frontal and parietal cortex, but
there was no difference in the decoding accuracy of task-rela
16 There was no difference in the primary endpoint of day 1 dysp
17 r initial shockable rhythms (from 58.9% to 69.2%; P<0.001),
there was no difference in unadjusted rate of successful card
18 There was no direct evidence on the benefits or harms of scre
19 der certain conditions through a TBK1-binding domain (TBD),
there was no direct impact of the TBD on viral replication or
20 There was no effect against serotype 3.
21 There was no effect of MCH on fetal plasma/lung tissue cortis
22 There was no effect on endothelial function as measured by re
23 There was no evidence of a threshold in the exposure-response
24 There was no evidence of association between hemoglobin and b
25 There was no evidence of improvement in complete response wit
26 There was no evidence that iCST has an effect on cognition or
27 In addition, as with intracerebroventricular CGRP,
there was no general increase in anxiety as measured in an op
28 There was no increase in vascular occlusive events with trane
29 lthy controls and in older adults versus younger adults but
there was no interaction.
30 There was no interference in protection between the different
31 While
there was no observable benefit at early time points after tr
32 There was no shift to shorter acyl chain lengths observed, su
33 There was no significant association between younger age and
34 There was no significant association with sex or Chinese ethn
35 There was no significant between-group difference in change i
36 declined (-3.3%/y [95% CI, -5.6% to -1.0%], P = .004), but
there was no significant change in the combined outcome of de
37 There was no significant change of either hand grip strength
38 Overall,
there was no significant correlation between alveolar bone vo
39 There was no significant difference in mutation load in cance
40 There was no significant difference in response rates between
41 There was no significant difference in striatal Kicer between
42 There was no significant difference in the levels of inhibiti
43 There was no significant difference in the punctum diameter a
44 minary report of a trial involving patients undergoing PCI,
there was no significant difference in the rate of target-ves
45 Results
There was no significant difference in the size or shape of a
46 At 28 weeks,
there was no significant effect of either benralizumab regime
47 wer fields (AHR, 2.5; 95% CI, 1.1 to 6.0; P = .03), whereas
there was no significant effect of negative microscopic resec
48 There was no significant shift in dose-distribution curves du
49 There was no substantive deviation in postnatal growth trajec
50 There was no survival difference between PB-type cancers and